Lupin Diagnostics Limited, a wholly owned subsidiary of global pharmaceutical company Lupin, has announced that it has secured 100% NABL accreditation across all its greenfield laboratories in India. This makes Lupin Diagnostics one of the few diagnostic chains in the country to have all its facilities accredited by the National Accreditation Board for Testing and Calibration Laboratories (NABL).
In a statement released on April 23, 2025, Ravindra Kumar, CEO of Lupin Diagnostics, said, “This accreditation is a testament to the team’s dedication to patient care and our mission to promote healthier lives. The 27 greenfield labs across the country ensure timely and accurate reporting. Our goal is to empower doctors and patients with evidence-based diagnostics.”
The recognition reflects Lupin Diagnostics’ consistent focus on quality, operational efficiency, and patient-centric services. The company has been recognized with several national awards, including the ‘Patient-Centric Diagnostic Laboratories Company of the Year’ at the IHW 3rd Patients First Award 2024, and ‘Pathology Lab of the Year’ at the ET Healthcare Awards 2022 and 2024.
Founded in December 2021, Lupin Diagnostics started with a 45,000 sq. ft. National Reference Laboratory in Navi Mumbai and has since grown its footprint across West, South, East, and Central India. Its labs provide over 3,000 types of diagnostic tests, including molecular diagnostics, microbiology, cytology, immunology, and biochemistry.
This milestone marks a significant step in Lupin’s broader vision of enhancing healthcare infrastructure in India and promoting accurate, reliable, and accessible diagnostics to every corner of the country.
